Stockscreener 앱 받기
10.89
0.56%
0.08
시간 외 거래:
10.89
전일 마감가:
$10.81
열려 있는:
$10.81
하루 거래량:
21,575
Relative Volume:
0.44
시가총액:
$205.93M
수익:
-
순이익/손실:
$3.27M
주가수익비율:
64.86
EPS:
0.1679
순현금흐름:
$-647.10K
1주 성능:
+0.65%
1개월 성능:
+0.18%
6개월 성능:
+4.02%
1년 성능:
+5.95%
1일 변동 폭
$10.75
$10.89
1주일 범위
$10.70
$10.97
52주 변동 폭
$10.14
$11.59
Helix Acquisition Corp Ii Stock (HLXB) Company Profile
명칭
Helix Acquisition Corp Ii
전화
857 702 0377
주소
C/O CORMORANT ASSET MANAGEMENT, LP, BOSTON
HLXB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HLXB
Helix Acquisition Corp Ii
|
10.89 | 254.13M | 0 | 3.27M | -647.10K | 0.1679 |
|
LION
Lionsgate Studios Corp
|
6.70 | 1.91B | 2.82B | -191.60M | -407.10M | -0.6794 |
|
AACT
Ares Acquisition Corporation Ii
|
11.42 | 698.40M | 0 | 16.92M | -1.35M | 0.29 |
|
CEP
Cantor Equity Partners Inc
|
40.22 | 584.96M | 0 | 0 | 0 | 0.00 |
|
EQV
Eqv Ventures Acquisition Corp
|
10.51 | 465.34M | 0 | 0 | 0 | 0.00 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.77 | 463.16M | 0 | 1.30M | 0 | 0.0301 |
Helix Acquisition Corp Ii 주식(HLXB)의 최신 뉴스
Toronto Dominion Bank Buys New Shares in Helix Acquisition Corp. II (NASDAQ:HLXB) - MarketBeat
Toronto Dominion Bank Invests $520,000 in Helix Acquisition Corp. II (NASDAQ:HLXB) - MarketBeat
Big Law Firms Wary of SPAC Rebound Seek to Get Paid This Time - Bloomberg Law News
Helix BioPharma Expands Oncology Portfolio with Strategic Acquisition - TipRanks
Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group - TheNewswire
Helix Acquisition Corp. II SEC 10-Q Report - TradingView
Geode Capital Management LLC Acquires 119,943 Shares of Nuburu, Inc. (NYSEAMERICAN:BURU) - Defense World
Geode Capital Management LLC Acquires 16,862 Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) - Defense World
Geode Capital Management LLC Increases Stock Holdings in Helix Acquisition Corp. II (NASDAQ:HLXB) - Defense World
Crown Castle (NYSE:CCI) Upgraded at New Street Research - Defense World
National Bank Financial Predicts Cameco FY2026 Earnings - Defense World
DaVita Inc. (NYSE:DVA) Given Consensus Rating of “Hold” by Brokerages - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Swiss ADC Biotech Takes SPAC Track to NASDAQ - BioSpace
German cancer antibody biotech eyes SPAC as route to Nasdaq - Fierce Biotech
Harraden Circle Investments LLC Acquires Shares of 257,226 Helix Acquisition Corp. II (NASDAQ:HLXB) - MarketBeat
Helix BioPharma Corp. Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan - Yahoo Finance
MLTX stock touches 52-week low at $36.51 amid market shifts - Investing.com Australia
MLTX stock touches 52-week low at $36.51 amid market shifts By Investing.com - Investing.com South Africa
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors - Business Wire
Firm foundations: Can US IPO markets continue to build on solid gains? - Lexology
Decagon Asset Management LLP Invests $1.96 Million in Helix Acquisition Corp. II (NASDAQ:HLXB) - MarketBeat
Newsroom - White & Case LLP
GSK’s $1.15B Idrx buyout leads slow M&A market as deals stay strong - BioWorld Online
Bay Area VC-funded life sciences companies raised over $5 billion in 2024 - The Business Journals
Helix Exploration expands with key acquisition at Rudyard - Proactive Investors
Helix Acquisition Corp. II SEC 10-K Report - TradingView
MLTX stock touches 52-week low at $37.53 amid market shifts - Investing.com Australia
BBIOBridgebio Pharma Latest Stock News & Market Updates - StockTitan
Helix Acquisition Corp. II’s US$949 Million Business Combination with BridgeBio Oncology Therapeutics - Global Legal Chronicle
BridgeBio Oncology and Helix enter definitive merger agreement - MSN
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies - The Pharma Letter
White & Case advises Helix Acquisition Corp. II on its US$949 million business combination with BridgeBio Oncology Therapeutics - White & Case LLP
Helix Acquisition Corp. II (HLXB) to Combine with BridgeBio Oncology in $360M Deal - SPACInsider
Helix Acquisition Corp. II Merger with BridgeBio Oncology Therapeutics - Leerink Partners
Helix Acquisition Corp. II PIPE - Leerink Partners
Finance Watch: BridgeBio’s Oncology Spinout Reveals Go-Public Plan - insights.citeline.com
LZ Technology Closes $7.2 Million IPO -February 28, 2025 at 04:48 pm EST - Marketscreener.com
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs - MedCity News
Boston SPAC picks biotech to take public - The Business Journals
Goodwin, White & Case Build BridgeBio's $949M SPAC Deal - Law360
BridgeBio oncology spinout to go public in blank-check merger - BioPharma Dive
BridgeBio Oncology Takes Unexpected SPAC Track to Public Markets in $450M Deal - BioSpace
Helix Acquisition to Merge With BridgeBio Oncology Therapeutics - MarketScreener
BridgeBio's KRAS-focused cancer spinout backs SPAC as path to Nasdaq - Fierce Biotech
BridgeBio Oncology Therapeutics and Helix Acquisition Corp. II To Merge - citybiz
BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen - Endpoints News
$450M Deal Powers New Cancer-Fighting Biotech: What's Inside BridgeBio's Oncology SPAC Merger? - StockTitan
Helix Acquisition Corp Ii (HLXB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
0.10%
자본화:
|
볼륨(24시간):